Tofacitinib Reduces KL-6 Levels in Patients With Rheumatoid Arthritis-Associated Interstitial Lung Disease. Results Of A Phase II Investigator-Initiated Study.

Study limitation reported by the research below: “Study design is described as Phase II investigator-initiated without randomization — closest label is a single-arm interventional trial; study design tag reflects this.”